An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
AtriCure to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. A prerecorded fireside chat is scheduled for November 22, 2021, accessible via the company's website. Additionally, management will hold investor meetings on December 1, 2021. AtriCure focuses on innovative technologies for Afib management, impacting over 33 million people globally, with notable products including the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System.
Positive
None.
Negative
None.
MASON, Ohio--(BUSINESS WIRE)--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference.
AtriCure’s prerecorded fireside chat will be available on Monday, November 22, 2021 on the conference and company’s website. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com. Management will participate in investor meetings on Wednesday, December 1, 2021.
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
Angie Wirick AtriCure, Inc. Chief Financial Officer
(513) 755-5334
awirick@atricure.com
Lynn Lewis Gilmartin Group Investor Relations
(415) 937-5402
lynn@gilmartinir.com
Source: AtriCure, Inc.
FAQ
What is AtriCure's participation in the Piper Sandler Virtual Healthcare Conference?
AtriCure will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference with a prerecorded fireside chat available on November 22, 2021.
When will AtriCure hold investor meetings?
AtriCure's management will participate in investor meetings on December 1, 2021.
What is the significance of AtriCure's Isolator® Synergy™ Ablation System?
The Isolator® Synergy™ Ablation System is the first FDA-approved device for treating persistent atrial fibrillation.
How many people worldwide are affected by atrial fibrillation?
Atrial fibrillation affects more than 33 million people worldwide.
What innovative technologies does AtriCure offer?
AtriCure provides technologies for the treatment of atrial fibrillation, including the AtriClip® and Hybrid AF™ Therapy.
